ArticleInternational journal of nephrology and renovascular disease2016

The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients.

Omar Maoujoud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.